New York, May 17, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Myeloproliferative Disorders Drugs Industry" - https://www.reportlinker.com/p06032290/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global Myeloproliferative Disorders Drugs Market to Reach $12.9 Billion by 2030
In the changed post COVID-19 business landscape, the global market for Myeloproliferative Disorders Drugs estimated at US$9.3 Billion in the year 2022, is projected to reach a revised size of US$12.9 Billion by 2030, growing at aCAGR of 4.2% over the period 2022-2030. Ph+ Chronic myelogenous leukemia (CML), one of the segments analyzed in the report, is projected to record 3.5% CAGR and reach US$9.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Ph- Myeloproliferative Neoplasms (MPNs) segment is readjusted to a revised 6.1% CAGR for the next 8-year period.
The U.S. Market is Estimated at $2.5 Billion, While China is Forecast to Grow at 7.3% CAGR
The Myeloproliferative Disorders Drugs market in the U.S. is estimated at US$2.5 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.7 Billion by the year 2030 trailing a CAGR of 7.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.9% and 3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.8% CAGR.
Select Competitors (Total 34 Featured)
- Bristol-Myers Squibb
- Inctye
- Novartis
- Pfizer
- Takeda
- Teva
Read the full report: https://www.reportlinker.com/p06032290/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Impact of Covid-19 and a Looming Global Recession
Myeloproliferative Disorders Drugs - Global Key Competitors
Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Myeloproliferative Disorders Drugs by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 2: World Historic Review for Myeloproliferative Disorders
Drugs by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 3: World 16-Year Perspective for Myeloproliferative
Disorders Drugs by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets for
Years 2014, 2023 & 2030
Table 4: World Recent Past, Current & Future Analysis for Ph+
Chronic myelogenous leukemia (CML) by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 5: World Historic Review for Ph+ Chronic myelogenous
leukemia (CML) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 6: World 16-Year Perspective for Ph+ Chronic myelogenous
leukemia (CML) by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2014, 2023 & 2030
Table 7: World Recent Past, Current & Future Analysis for Ph-
Myeloproliferative Neoplasms (MPNs) by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 8: World Historic Review for Ph- Myeloproliferative
Neoplasms (MPNs) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 9: World 16-Year Perspective for Ph- Myeloproliferative
Neoplasms (MPNs) by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2014, 2023 & 2030
Table 10: World Myeloproliferative Disorders Drugs Market
Analysis of Annual Sales in US$ Million for Years 2014 through
2030
III. MARKET ANALYSIS
UNITED STATES
Myeloproliferative Disorders Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in the United States
for 2023 (E)
Table 11: USA Recent Past, Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 12: USA Historic Review for Myeloproliferative Disorders
Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML)
and Ph- Myeloproliferative Neoplasms (MPNs) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 13: USA 16-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 &
2030
CANADA
Table 14: Canada Recent Past, Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 15: Canada Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 16: Canada 16-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 &
2030
JAPAN
Myeloproliferative Disorders Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
Table 17: Japan Recent Past, Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 18: Japan Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 19: Japan 16-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 &
2030
CHINA
Myeloproliferative Disorders Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in China for 2023 (E)
Table 20: China Recent Past, Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 21: China Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 22: China 16-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 &
2030
EUROPE
Myeloproliferative Disorders Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
Table 23: Europe Recent Past, Current & Future Analysis for
Myeloproliferative Disorders Drugs by Geographic Region -
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 24: Europe Historic Review for Myeloproliferative
Disorders Drugs by Geographic Region - France, Germany, Italy,
UK, Spain, Russia and Rest of Europe Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 25: Europe 16-Year Perspective for Myeloproliferative
Disorders Drugs by Geographic Region - Percentage Breakdown of
Value Sales for France, Germany, Italy, UK, Spain, Russia and
Rest of Europe Markets for Years 2014, 2023 & 2030
Table 26: Europe Recent Past, Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 27: Europe Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 28: Europe 16-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 &
2030
FRANCE
Myeloproliferative Disorders Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in France for 2023 (E)
Table 29: France Recent Past, Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 30: France Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 31: France 16-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 &
2030
GERMANY
Myeloproliferative Disorders Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
Table 32: Germany Recent Past, Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 33: Germany Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 34: Germany 16-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 &
2030
ITALY
Table 35: Italy Recent Past, Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 36: Italy Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 37: Italy 16-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 &
2030
UNITED KINGDOM
Myeloproliferative Disorders Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in the United Kingdom
for 2023 (E)
Table 38: UK Recent Past, Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 39: UK Historic Review for Myeloproliferative Disorders
Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML)
and Ph- Myeloproliferative Neoplasms (MPNs) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 40: UK 16-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 &
2030
SPAIN
Table 41: Spain Recent Past, Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 42: Spain Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 43: Spain 16-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 &
2030
RUSSIA
Table 44: Russia Recent Past, Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 45: Russia Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 46: Russia 16-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 &
2030
REST OF EUROPE
Table 47: Rest of Europe Recent Past, Current & Future Analysis
for Myeloproliferative Disorders Drugs by Indication - Ph+
Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative
Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 48: Rest of Europe Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 49: Rest of Europe 16-Year Perspective for
Myeloproliferative Disorders Drugs by Indication - Percentage
Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia
(CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years
2014, 2023 & 2030
ASIA-PACIFIC
Myeloproliferative Disorders Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Asia-Pacific for
2023 (E)
Table 50: Asia-Pacific Recent Past, Current & Future Analysis
for Myeloproliferative Disorders Drugs by Geographic Region -
Australia, India, South Korea and Rest of Asia-Pacific Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR
Table 51: Asia-Pacific Historic Review for Myeloproliferative
Disorders Drugs by Geographic Region - Australia, India, South
Korea and Rest of Asia-Pacific Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 52: Asia-Pacific 16-Year Perspective for
Myeloproliferative Disorders Drugs by Geographic Region -
Percentage Breakdown of Value Sales for Australia, India, South
Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 &
2030
Table 53: Asia-Pacific Recent Past, Current & Future Analysis
for Myeloproliferative Disorders Drugs by Indication - Ph+
Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative
Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 54: Asia-Pacific Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 55: Asia-Pacific 16-Year Perspective for
Myeloproliferative Disorders Drugs by Indication - Percentage
Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia
(CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years
2014, 2023 & 2030
AUSTRALIA
Myeloproliferative Disorders Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Australia for 2023
(E)
Table 56: Australia Recent Past, Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 57: Australia Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 58: Australia 16-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 &
2030
INDIA
Myeloproliferative Disorders Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in India for 2023 (E)
Table 59: India Recent Past, Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 60: India Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 61: India 16-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 &
2030
SOUTH KOREA
Table 62: South Korea Recent Past, Current & Future Analysis
for Myeloproliferative Disorders Drugs by Indication - Ph+
Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative
Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 63: South Korea Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 64: South Korea 16-Year Perspective for
Myeloproliferative Disorders Drugs by Indication - Percentage
Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia
(CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years
2014, 2023 & 2030
REST OF ASIA-PACIFIC
Table 65: Rest of Asia-Pacific Recent Past, Current & Future
Analysis for Myeloproliferative Disorders Drugs by Indication -
Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 66: Rest of Asia-Pacific Historic Review for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 67: Rest of Asia-Pacific 16-Year Perspective for
Myeloproliferative Disorders Drugs by Indication - Percentage
Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia
(CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years
2014, 2023 & 2030
LATIN AMERICA
Myeloproliferative Disorders Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Latin America for
2023 (E)
Table 68: Latin America Recent Past, Current & Future Analysis
for Myeloproliferative Disorders Drugs by Geographic Region -
Argentina, Brazil, Mexico and Rest of Latin America Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR
Table 69: Latin America Historic Review for Myeloproliferative
Disorders Drugs by Geographic Region - Argentina, Brazil,
Mexico and Rest of Latin America Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 70: Latin America 16-Year Perspective for
Myeloproliferative Disorders Drugs by Geographic Region -
Percentage Breakdown of Value Sales for Argentina, Brazil,
Mexico and Rest of Latin America Markets for Years 2014, 2023 &
2030
Table 71: Latin America Recent Past, Current & Future Analysis
for Myeloproliferative Disorders Drugs by Indication - Ph+
Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative
Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 72: Latin America Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 73: Latin America 16-Year Perspective for
Myeloproliferative Disorders Drugs by Indication - Percentage
Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia
(CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years
2014, 2023 & 2030
ARGENTINA
Table 74: Argentina Recent Past, Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 75: Argentina Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 76: Argentina 16-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 &
2030
BRAZIL
Table 77: Brazil Recent Past, Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 78: Brazil Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 79: Brazil 16-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 &
2030
MEXICO
Table 80: Mexico Recent Past, Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 81: Mexico Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 82: Mexico 16-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 &
2030
REST OF LATIN AMERICA
Table 83: Rest of Latin America Recent Past, Current & Future
Analysis for Myeloproliferative Disorders Drugs by Indication -
Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 84: Rest of Latin America Historic Review for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 85: Rest of Latin America 16-Year Perspective for
Myeloproliferative Disorders Drugs by Indication - Percentage
Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia
(CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years
2014, 2023 & 2030
MIDDLE EAST
Myeloproliferative Disorders Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Middle East for 2023
(E)
Table 86: Middle East Recent Past, Current & Future Analysis
for Myeloproliferative Disorders Drugs by Geographic Region -
Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR
Table 87: Middle East Historic Review for Myeloproliferative
Disorders Drugs by Geographic Region - Iran, Israel, Saudi
Arabia, UAE and Rest of Middle East Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 88: Middle East 16-Year Perspective for
Myeloproliferative Disorders Drugs by Geographic Region -
Percentage Breakdown of Value Sales for Iran, Israel, Saudi
Arabia, UAE and Rest of Middle East Markets for Years 2014,
2023 & 2030
Table 89: Middle East Recent Past, Current & Future Analysis
for Myeloproliferative Disorders Drugs by Indication - Ph+
Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative
Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 90: Middle East Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 91: Middle East 16-Year Perspective for
Myeloproliferative Disorders Drugs by Indication - Percentage
Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia
(CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years
2014, 2023 & 2030
IRAN
Table 92: Iran Recent Past, Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 93: Iran Historic Review for Myeloproliferative Disorders
Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML)
and Ph- Myeloproliferative Neoplasms (MPNs) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 94: Iran 16-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 &
2030
ISRAEL
Table 95: Israel Recent Past, Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 96: Israel Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 97: Israel 16-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 &
2030
SAUDI ARABIA
Table 98: Saudi Arabia Recent Past, Current & Future Analysis
for Myeloproliferative Disorders Drugs by Indication - Ph+
Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative
Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 99: Saudi Arabia Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR
Table 100: Saudi Arabia 16-Year Perspective for
Myeloproliferative Disorders Drugs by Indication - Percentage
Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia
(CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years
2014, 2023 & 2030
UNITED ARAB EMIRATES
Table 101: UAE Recent Past, Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 102: UAE Historic Review for Myeloproliferative Disorders
Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML)
and Ph- Myeloproliferative Neoplasms (MPNs) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 103: UAE 16-Year Perspective for Myeloproliferative
Disorders Drugs by Indication - Percentage Breakdown of Value
Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 &
2030
REST OF MIDDLE EAST
Table 104: Rest of Middle East Recent Past, Current & Future
Analysis for Myeloproliferative Disorders Drugs by Indication -
Ph+ Chronic myelogenous leukemia (CML) and Ph-
Myeloproliferative Neoplasms (MPNs) - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 105: Rest of Middle East Historic Review for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 106: Rest of Middle East 16-Year Perspective for
Myeloproliferative Disorders Drugs by Indication - Percentage
Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia
(CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years
2014, 2023 & 2030
AFRICA
Myeloproliferative Disorders Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
Table 107: Africa Recent Past, Current & Future Analysis for
Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic
myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms
(MPNs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 108: Africa Historic Review for Myeloproliferative
Disorders Drugs by Indication - Ph+ Chronic myelogenous
leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs)
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06032290/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
